| INTRODUCTION
Atrial fibrillation (AF) is the most common cardiac arrhythmia, with a reported 2% prevalence among all medicare beneficiaries <65 years old and 9% ≥65 years old, and an estimated 2-10% annual stroke risk depending on individual risk factors.
1,2 Anticoagulation strategies for reducing the incidence of cerebral and systemic thromboembolism in the setting of non-valvular AF (NVAF) have relied on risk score systems including the CHADS 2 and the more current CHA 2 DS 2 -VASc scores. The CHA 2 DS 2 -VASc score, which has more discriminatory power in individuals characterized as low risk by CHADS 2 , was described and validated in 2009, and defines congestive heart failure (CHF) as a left ventricular ejection fraction (LVEF) ≤40%, or signs or symptoms of right or left heart failure (HF). 1, [3] [4] [5] The American College of Cardiology/American Heart Association/Heart Rhythm Society (ACC/AHA/HRS) and European Society of Cardiology (ESC) all recommend using the CHA 2 DS 2 -VASc score to risk stratify individuals with AF to inform anticoagulation decisions. 2, 5 Even though congestive HF has been validated as an independent risk factor for stroke regardless of ejection fraction, the clinical significance of HF with preserved ejection fraction (HFpEF) may be underappreciated. Approximately, 50% of all patients with HF have HFpEF, with cross-sectional studies reporting rates between 40% to 71% depending on the EF cutoff (40%-50%) used to define HFpEF, and longitudinal studies showing an increasing prevalence over time. [6] [7] [8] [9] [10] [11] Practice patterns regarding the prescription of anticoagulation for patients with NVAF and HFpEF or HFrEF have not been well characterized and guideline adherence remains unknown. Prior studies in the HF population have reported varying rates of anticoagulation in those with NVAF, with one meta-analysis that aggregated unadjusted data from 10 studies showing lower rates in the HFpEF compared to the HFrEF population, and another study, which showed after risk adjustment, equal rates of anticoagulation in inpatients with HFpEF or HFrEF (11, 17) . The aim of this study was to characterize current outpatient practice patterns regarding the use of anticoagulation in a large cohort of outpatient patients with NVAF and CHF. By characterizing rates of oral anticoagulation in patients with HFpEF compared to HFrEF, we hope to identify gaps between practice patterns and anticoagulation guidelines in patients with AF and HF.
2 | METHODS
| Data collection
We retrospectively analyzed a series of 6 746 301 consecutive patients who were prospectively entered into the American College 
| Definitions and study endpoints
The primary predictor variable was CHF group, with patients classified into two subgroups: HFpEF (LVEF ≥ 40%) and HFrEF (LVEF < 40% 3 | RESULTS
| Study population
A total of 340 127 patients with congestive HF and NVAF were included in the study. Of these, 248 136 (73.0%) and 91 991 (27.0%)
were identified as patients with HFpEF and HFrEF, respectively. were all associated with increased use of anticoagulation (P < 0.001).
Female gender and vascular disease were associated with lower rates (P < 0.001). See Table S1 
| Anticoagulation over time

| DISCUSSION
Within our outpatient study population of individuals with NVAF and CHF, 69% of these patients had HFpEF. Although this falls within the upper range of what has been previously reported, 6-10 the outpatient study cohort used was contemporary and is consistent with prior studies suggesting that HFpEF is a growing clinical entity. Importantly, our study showed that although HFpEF patients with NVAF had higher average CHA 2 DS 2 -VASc scores, their overall rates of anticoagulation compared to their HFrEF counterparts were lower. Thus, even though data from observational studies and clinical trials show comparable rates of stroke/TIA within the reduced and preserved ejection fractions HF groups with AF, [14] [15] [16] there remains a discrepancy in rates of anticoagulation between these groups in the outpatient. Importantly, even though HFpEF patients are less likely to be anticoagulated than HFrEF patients, rates of anticoagulation in both groups has increased over time.
Prior studies evaluating rates of anticoagulation in HF patients with AF have shown variable anticoagulation rates depending on the FIGURE 2 Relative risks for oral anticoagulation by baseline patient characteristics. Relative risks from the variables included in the multivariable model for predicting anticoagulation. CABG, coronary artery bypass graft; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction, PCI percutaneous coronary intervention, TIA, transient ischemic attack FIGURE 3 Risk adjusted rates of anticoagulation by heart failure group and CHA2DS2-VASc score. HFpEF, heart failure with preserved ejection fraction; HFrEF heart failure with reduced ejection fraction study population evaluated and whether or not the data were risk adjusted. 6, 14, 15 In one observational study by Steinberg et al. which used inpatient registry data, lower unadjusted rate of anticoagulation in the HFpEF group compared to the HFrEF group resolved after risk adjustment. 6 In the Sartipy et al study which used inpatient and outpatient data unadjusted rates of anticoagulation in patients with
HFrEF were higher compared to those with HFpEF. 15 Interestingly, this study found in multivariable analysis that anticoagulant use in patients with HFpEF was more likely to be associated with NVAF than in patients with HFrEF. 15 This suggests that the HFrEF population may be more likely to have additional indications for anticoagulation compared to the HFpEF group, and may be why differences in anticoagulation rates between these two groups decrease after risk adjustment.
Our study provides insight into current outpatient anticoagulation patterns in patients with HF and AF. Although it is unclear why patients with HFpEF are less likely to be anticoagulated than those with HFrEF, this difference suggests that opportunities for improving rates of anticoagulation in this patient population exist. Central to the pathogenesis of HFpEF is the systemic inflammation resulting from the comorbid conditions including obesity, DM, HTN, and renal failure associated with it. 17 Because of its heterogeneity, it is possible that patients with Our study has several limitations. This study involved an outpatient data registry that relies on manual entry and standardized algorithms for extracting data from the electronic medical records, so data completion was not 100%. Thus, the results only characterize outpatient patterns of anticoagulation prescription and are not generalizable to the entire population. In addition, HF classification relied on both quantitative and qualitative assessments of ejection fraction, and misclassification may have occurred. In addition, because this is not a prospective dataset being collected for the hypothesis being evaluated, there are data constraints including an inability to assess patient preferences, as well as other indications for anticoagulation, such as deep venous thromboembolism in our dataset. Resultantly, it was not possible to discriminate between and exclude individuals who had a contraindication to anticoagulation or an indication to anticoagulation other than AF in this dataset. Instead, as is convention with analyses using the PINNACLE dataset, we relied on a data field indicating medical contraindication to anticoagulation to exclude individuals from analysis. Longitudinal data was also not present, and instead only a snapshot of anticoagulation rates could be provided, and no outcomes data including rates of stroke/TIA, or medication adherence was available.
FIGURE 4
Observed rates of anticoagulation by heart failure group and year. This graphic shows the temporal trend in observed rates of anticoagulation in the congestive heart failure population (total and by heart failure group) with non-valvular atrial fibrillation. Comparison between the observed rates of anticoagulation between the heart failure groups by year were made. *P < 0.05, HFpEF, heart failure with preserved ejection fraction; HFrEF heart failure with reduced ejection fraction
| CONCLUSIONS
The majority of outpatients with NVAF and CHF have HFpEF, and even though these individuals have higher CHA 2 DS 2 -VASc scores, they are significantly less likely to be prescribed oral anticoagulation compared to HFrEF patients. The discrepancy in anticoagulation rate is most prevalent in the lower risk groups, and may be secondary to differences in guideline recommendations and evidence for anticoagulating individuals when bleeding is a risk. Future studies are needed to clarify why differences exist in anticoagulation by HF type; however, our data calls for educating and alerting clinicians of this important risk factor for stroke prevention.
| CLINICAL PERSPECTIVES
Congestive HF has been validated as an independent risk factor for stroke regardless of ejection fraction; however, the clinical significance of HF with preserved EF may be underappreciated. The majority of outpatients with NVAF and congestive HF have preserved ejection fraction. Even though these individuals have higher CHA2DS2-VASc scores, they are significantly less likely to be prescribed oral anticoagulation compared to outpatients with HF with reduced EF which suggests an opportunity for educating and alerting clinicians of this important risk factor for stroke prevention.
| TRANSLATIONAL OUTLOOK
Future studies are needed to clarify why differences exist in anticoagulation by HF type, and in particular why individuals with AF and HF with preserved EF are less likely to anticoagulated than their reduced EF counterparts.
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